Document is current
Any future updates will be listed below
-
Authors
Roberts, Timothy P. L. https://orcid.org/0000-0001-7320-4870
Kuschner, Emily S.
Edgar, J. Christopher
-
Funding
Funding for this research was provided by:
National Institute on Deafness and Other Communication Disorders (R01-DC008871)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54-HD086954)
- License Information
-
More Information
Article History
Received: 26 November 2020
Accepted: 3 May 2021
First Online: 15 September 2021
Declarations
:
: All data described in this study was collected under protocols that had been approved by the CHOP institutional review board. Written informed consent was obtained from parents/caregivers, and where competent, assent was obtained from all children > 7 years of age.
: Participants consented to unidentifiable publication of the results of their research participation.
: Dr. Roberts declares his position on the advisory boards of (1) CTF MEG, (2) Ricoh, (3) Spago Nanomedicine, (4) Avexis Inc., and (5) Acadia Pharmaceuticals and equity interests in (1) Prism Clinical Imaging and (2) Proteus Neurodynamics. Dr. Roberts and Dr. Edgar also declare intellectual property relating to the potential use of electrophysiological markers for treatment planning in clinical ASD. Dr. Edgar declares no other financial conflict. Dr. Kuschner declares no financial conflicts.
